Biotechnology

Zelgen

Zelgen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 905.39 M, actual EPS CNY 2.39

Zelgen to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Zelgen to release FY2025 earnings report on March 28 During-Market (BJT), forecast revenue CNY 843.69 M, EPS CNY -0.3333

Zelgen released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 810.48 M (forecast CNY 843.69 M), actual EPS CNY -0.62 (forecast CNY -0.3333)

Zelgen released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 219.29 M, actual EPS CNY -0.2658

Zelgen released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 217.79 M, actual EPS CNY -0.0734

Zelgen released FY2025 9 Months earnings on October 30 After-Market BJT, actual revenue CNY 593.44 M, actual EPS CNY -0.3527

Zelgen to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Zelgen released FY2025 Semi-Annual earnings on August 22 After-Market (BJT), actual revenue CNY 375.65 M, actual EPS CNY -0.28

Zelgen released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 208.01 M, actual EPS CNY 0

Zelgen to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Zelgen Biopharma Publishes International Patent Application

Zelgen Pharmaceutical's Key Drug Sales and R&D Progress

Zelgen Pharmaceutical Receives ATSA's First Advance Payment of RMB 50 Million

Zelgen Pharma Announces International Patent Application and R&D Data

ZELIN Pharmaceutical stock price hits new high

ZG006 demonstrates outstanding efficacy, positioning for SCLC market

ZG006 Listed as Breakthrough Therapy Designation by NMPA

Huansan Securities Issues Buy Rating Report on Jayzen Pharmaceutical

Ping An Fund Surveys ZEJING Pharmaceutical, Jicotinib Hydrochloride Tablets Approved for Market

688266

ZeJing Pharma announced that its injectable human thyrotropin beta has met the primary endpoint in its Phase III clinical trial for differentiated thyroid cancer. The trial demonstrated expected efficacy and safety results. The company plans to submit a Pre-BLA communication application to the CDE to advance the market approval process. Detailed data will be presented at future clinical academic conferences.

CoinLive

ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary Endpoint

As global markets show mixed performances, investors are focusing on undervalued Asian stocks. Notable mentions include WuXi XDC Cayman, Visional, and Suzhou Zelgen Biopharmaceuticals, with discounts to fair value reaching up to 49.9%. Companies like Nanjing Leads Biolabs and Sino Medical Sciences Technology are highlighted for their growth potential, with significant earnings growth projected. The article emphasizes the strategic advantage of investing in these undervalued stocks amidst current market conditions, suggesting potential for substantial returns as the market stabilizes.

Simplywall

3 Asian Stocks Estimated To Be Undervalued By Up To 49.6%

Zelgen announced that its self-developed Jikaxitinib hydrochloride tablets achieved the primary efficacy endpoint in the Phase III clinical trial for the treatment of active ankylosing spondylitis, with statistical significance (p<0.0001). The company will accelerate the drug's market launch process

Zhitong

Zelgen: The Phase III clinical trial of Hydrochloride Gikaxitin Tablets for the treatment of active ankylosing spondylitis has reached the primary efficacy endpoint

300811

As global markets face uncertainty, companies with high insider ownership are gaining attention for their growth potential. Notable firms include Suzhou Zelgen Biopharmaceuticals, expected to grow revenue by 38% annually, and Beijing Relpow Technology, with a forecast of 32.7% growth. POCO Holding anticipates a 22.7% revenue increase. Despite recent losses, these companies show promise for future profitability, although share price volatility remains a concern for investors.

POCO

3 Global Growth Companies With High Insider Ownership Expecting 38% Revenue Growth

Zelgen recently received approval from the National Medical Products Administration for the clinical trial of injectable ZGGS34 for MUC17 positive advanced solid tumors. ZGGS34 is a trispecific antibody drug that can connect tumor cells with T cells, activating T cells to kill tumor cells. Compared to traditional T cell engagers, ZGGS34 introduces a CD28 agonistic antibody, enhancing T cell activation and anti-tumor effects. Preclinical studies have shown that ZGGS34 has significant inhibitory effects in various tumor models and demonstrates good safety characteristics in non-human primates

Zelgen: Injectable ZGGS34 has received approval for clinical trials

Zelgen announced that its injectable ZG006 has received conditional approval from the National Medical Products Administration to conduct critical clinical trials and has completed the enrollment of the first subject. ZG006 is a trispecific antibody drug targeting DLL3 and CD3, with potent tumor-killing effects, and has been included in the list of breakthrough therapies, indicated for the treatment of advanced small cell lung cancer

Zelgen: Injectable ZG006 initiates key clinical trials and completes enrollment of the first subject

Zelgen announced that it will present clinical research data for its new drugs ZG006 and ZG005 at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) from September 10 to 14, 2025. The Phase II clinical study of ZG006 targets patients with refractory advanced small cell lung cancer, while ZG005 is undergoing Phase I/II studies in first-line advanced neuroendocrine cancer patients

Zelgen: Clinical data for ZG006 and ZG005 released at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO)

Zelgen recently received approval from the National Medical Products Administration to conduct clinical trials for the combination of injectable ZG005, ZGGS18, and JAK inhibitor hydrochloride tablets for advanced solid tumors. ZG005 is an innovative tumor immunotherapy biological product and one of the first drugs targeting the same site to enter clinical research globally; ZGGS18 is a bifunctional antibody fusion protein with the potential to treat solid tumors; JAK inhibitor hydrochloride is a novel dual inhibitor of JAK and ACVR1 with independent intellectual property rights

Zelgen: Clinical trials for injectable ZG005, injectable ZGGS18, and hydrochloride gilteritinib tablets combined for advanced solid tumors have been approved

According to the Zhitong Finance APP, Zelgen announced that the company recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of injectable ZG005 combined with Jikaxitinib hydrochloride tablets and chemotherapy for advanced solid tumors

Zelgen: Injectable ZG005 combined with Hydrochloride Gilteritinib Tablets and chemotherapy has received approval for clinical trials

Zelgen announced that its clinical trial application for injectable ZGGS34 has been approved by the FDA, aimed at treating advanced solid tumors. ZGGS34 is a trispecific antibody drug targeting CD3 and CD28 on T cells and the tumor-associated antigen MUC17, demonstrating significant tumor suppression effects and good safety characteristics

Zelgen(688266.SH)